Session

Molecular and transitional aspects of PDHC

ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS AND NEUTROPENIA CAUSED BY TRIPLET CHEMOTHERAPY IN PATIENTS WITH PANCREATIC CANCER
ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS AND NEUTROPENIA CAUSED BY TRIPLET CHEMOTHERAPY IN PATIENTS WITH PANCREATIC CANCER

Molecular and transitional aspects of PDHC  et al.

PATHOLOGICAL ASSESSMENT OF TERTIARY LYMPHOID STRUCTURES IN PANCREATIC CANCER: DEVELOPMENT AND VALIDATION OF A NOVEL HEMATOXYLIN-EOSIN BASED CLASSIFICATION
PATHOLOGICAL ASSESSMENT OF TERTIARY LYMPHOID STRUCTURES IN PANCREATIC CANCER: DEVELOPMENT AND VALIDATION OF A NOVEL HEMATOXYLIN-EOSIN BASED CLASSIFICATION

Molecular and transitional aspects of PDHC  et al.

SMALL NON-FUNCTIONAL NEUROENDOCRINE PANCREATIC INCIDENTALOMAS (≤ 2 CM): RISK OF PROGRESSION OVER 3 YEARS. RESULTS OF THE PROSPECTIVE MULTICENTER FRENCH NATIONAL STUDY IPANEMA
SMALL NON-FUNCTIONAL NEUROENDOCRINE PANCREATIC INCIDENTALOMAS (≤ 2 CM): RISK OF PROGRESSION OVER 3 YEARS. RESULTS OF THE PROSPECTIVE MULTICENTER FRENCH NATIONAL STUDY IPANEMA

Molecular and transitional aspects of PDHC  et al.

COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)
COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)

Molecular and transitional aspects of PDHC  et al.

PREDICTING RISK OF PANCREATIC ADENOCARCINOMA IN PATIENTS WITH NEW-ONSET DIABETES MELLITUS
PREDICTING RISK OF PANCREATIC ADENOCARCINOMA IN PATIENTS WITH NEW-ONSET DIABETES MELLITUS

Molecular and transitional aspects of PDHC  et al.

SMALL NON-FUNCTIONAL NEUROENDOCRINE PANCREATIC INCIDENTALOMAS (≤ 2 CM): RISK OF PROGRESSION OVER 3 YEARS. RESULTS OF THE PROSPECTIVE MULTICENTER FRENCH NATIONAL STUDY IPANEMA
SMALL NON-FUNCTIONAL NEUROENDOCRINE PANCREATIC INCIDENTALOMAS (≤ 2 CM): RISK OF PROGRESSION OVER 3 YEARS. RESULTS OF THE PROSPECTIVE MULTICENTER FRENCH NATIONAL STUDY IPANEMA

ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS AND NEUTROPENIA CAUSED BY TRIPLET CHEMOTHERAPY IN PATIENTS WITH PANCREATIC CANCER
ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS AND NEUTROPENIA CAUSED BY TRIPLET CHEMOTHERAPY IN PATIENTS WITH PANCREATIC CANCER

PREDICTING RISK OF PANCREATIC ADENOCARCINOMA IN PATIENTS WITH NEW-ONSET DIABETES MELLITUS
PREDICTING RISK OF PANCREATIC ADENOCARCINOMA IN PATIENTS WITH NEW-ONSET DIABETES MELLITUS

PATHOLOGICAL ASSESSMENT OF TERTIARY LYMPHOID STRUCTURES IN PANCREATIC CANCER: DEVELOPMENT AND VALIDATION OF A NOVEL HEMATOXYLIN-EOSIN BASED CLASSIFICATION
PATHOLOGICAL ASSESSMENT OF TERTIARY LYMPHOID STRUCTURES IN PANCREATIC CANCER: DEVELOPMENT AND VALIDATION OF A NOVEL HEMATOXYLIN-EOSIN BASED CLASSIFICATION

COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)
COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)

Item 1 - 10 / 10
1